Brief: Suven Life Sciences' Pashamylarams Unit successfully completes USFDA inspection
July 21 (Reuters) - Suven Life Sciences Ltd SUVP.NS : * Co's pashamylarams unit successfully completes US FDA inspection; gets eir for pashamylarams unit * Source text: http://bit.ly/2acI4kH * Further company coverage SUVP.NS ((Bengaluru Newsroom; +91 80 6749 1130))
Recent news on Suven Life Sciences
See all newsBrief: Suven Life Sciences Completes Patient Enrollment In Global Phase-3 Masupirdine Study
India's Suven Life Sciences gains after Masupirdine Phase-3 study completes patient enrollment
Brief: Suven Life Sciences Completes Phase-1 Study Of SUVN-I6107, Advances To Phase-2
Brief: Suven Life Sciences Reports Positive DSMB Safety Review For Phase-3 Masupirdine Study
Brief: Suven Life Sciences Records 100% Patient Enrolment Milestone In Phase-2B Clinical Trial Of Ropanicant